CNGB3-achromatopsia clinical trial with CNTF: Diminished rod pathway responses with no evidence of improvement in cone function

Wadih M. Zein, Brett G. Jeffrey, Henry E. Wiley, Amy E. Turriff, Santa J. Tumminia, Weng Tao, Ronald A. Bush, Dario Marangoni, Rong Wen, Lisa L. Wei, Paul A. Sieving

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

PURPOSE: Ciliary neurotrophic factor (CNTF) protects rod photoreceptors from retinal degenerative disease in multiple nonhuman models. Thus far, CNTF has failed to demonstrate rod protection in trials for human retinitis pigmentosa. Recently, CNTF was found to improve cone photoreceptor function in a canine CNGB3 achromatopsia model. This study explores whether this finding translates to humans with CNGB3 achromatopsia.

METHODS: A five-subject, open-label Phase I/II study was initiated by implanting intraocular microcapsules releasing CNTF (nominally 20 ng/d) into one eye each of CNGB3 achromat participants. Fellow eyes served as untreated controls. Subjects were followed for 1 year.

RESULTS: Pupil constriction in treated eyes gave evidence of intraocular CNTF release. Additionally, scotopic ERG responses were reduced, and dark-adapted psychophysical absolute thresholds were increased, attributable to diminished rod or rod pathway activity. Optical coherence tomography revealed that the cone-rich fovea underwent structural changes as the foveal hyporeflective zone (HRZ) became diminished in CNTF-treated eyes. No objectively measurable enhancement of cone function was found by assessments of visual acuity, mesopic increment sensitivity threshold, or the photopic ERG. Careful measurements of color hue discrimination showed no change. Nonetheless, subjects reported beneficial changes of visual function in the treated eyes, including reduced light sensitivity and aversion to bright light, which may trace to decreased effective ambient light from the pupillary constriction; further they noted slowed adaptation to darkness, consistent with CNTF action on rod photoreceptors.

CONCLUSIONS: Ciliary neurotrophic factor did not measurably enhance cone function, which reveals a species difference between human and canine CNGB3 cones in response to CNTF. (ClinicalTrials.gov number, NCT01648452.).

Original languageEnglish
Pages (from-to)6301-6308
Number of pages8
JournalInvestigative Ophthalmology and Visual Science
Volume55
Issue number10
DOIs
StatePublished - Jan 1 2014

Fingerprint

Color Vision Defects
Ciliary Neurotrophic Factor
Clinical Trials
Retinal Rod Photoreceptor Cells
Constriction
Canidae
Retinal Cone Photoreceptor Cells
Light
Retinal Diseases
Photophobia
Retinitis Pigmentosa
Darkness
Optical Coherence Tomography
Pupil
Visual Acuity
Capsules
Color

Keywords

  • Achromatopsia
  • CNGB3
  • CNTF
  • CNTF-releasing implant
  • Cone photoreceptor
  • ECT implant
  • Human clinical trial
  • Rod photoreceptor

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

CNGB3-achromatopsia clinical trial with CNTF : Diminished rod pathway responses with no evidence of improvement in cone function. / Zein, Wadih M.; Jeffrey, Brett G.; Wiley, Henry E.; Turriff, Amy E.; Tumminia, Santa J.; Tao, Weng; Bush, Ronald A.; Marangoni, Dario; Wen, Rong; Wei, Lisa L.; Sieving, Paul A.

In: Investigative Ophthalmology and Visual Science, Vol. 55, No. 10, 01.01.2014, p. 6301-6308.

Research output: Contribution to journalArticle

Zein, WM, Jeffrey, BG, Wiley, HE, Turriff, AE, Tumminia, SJ, Tao, W, Bush, RA, Marangoni, D, Wen, R, Wei, LL & Sieving, PA 2014, 'CNGB3-achromatopsia clinical trial with CNTF: Diminished rod pathway responses with no evidence of improvement in cone function', Investigative Ophthalmology and Visual Science, vol. 55, no. 10, pp. 6301-6308. https://doi.org/10.1167/iovs.14-14860
Zein, Wadih M. ; Jeffrey, Brett G. ; Wiley, Henry E. ; Turriff, Amy E. ; Tumminia, Santa J. ; Tao, Weng ; Bush, Ronald A. ; Marangoni, Dario ; Wen, Rong ; Wei, Lisa L. ; Sieving, Paul A. / CNGB3-achromatopsia clinical trial with CNTF : Diminished rod pathway responses with no evidence of improvement in cone function. In: Investigative Ophthalmology and Visual Science. 2014 ; Vol. 55, No. 10. pp. 6301-6308.
@article{3a32fe8c030b451197f3e673d7d167bb,
title = "CNGB3-achromatopsia clinical trial with CNTF: Diminished rod pathway responses with no evidence of improvement in cone function",
abstract = "PURPOSE: Ciliary neurotrophic factor (CNTF) protects rod photoreceptors from retinal degenerative disease in multiple nonhuman models. Thus far, CNTF has failed to demonstrate rod protection in trials for human retinitis pigmentosa. Recently, CNTF was found to improve cone photoreceptor function in a canine CNGB3 achromatopsia model. This study explores whether this finding translates to humans with CNGB3 achromatopsia.METHODS: A five-subject, open-label Phase I/II study was initiated by implanting intraocular microcapsules releasing CNTF (nominally 20 ng/d) into one eye each of CNGB3 achromat participants. Fellow eyes served as untreated controls. Subjects were followed for 1 year.RESULTS: Pupil constriction in treated eyes gave evidence of intraocular CNTF release. Additionally, scotopic ERG responses were reduced, and dark-adapted psychophysical absolute thresholds were increased, attributable to diminished rod or rod pathway activity. Optical coherence tomography revealed that the cone-rich fovea underwent structural changes as the foveal hyporeflective zone (HRZ) became diminished in CNTF-treated eyes. No objectively measurable enhancement of cone function was found by assessments of visual acuity, mesopic increment sensitivity threshold, or the photopic ERG. Careful measurements of color hue discrimination showed no change. Nonetheless, subjects reported beneficial changes of visual function in the treated eyes, including reduced light sensitivity and aversion to bright light, which may trace to decreased effective ambient light from the pupillary constriction; further they noted slowed adaptation to darkness, consistent with CNTF action on rod photoreceptors.CONCLUSIONS: Ciliary neurotrophic factor did not measurably enhance cone function, which reveals a species difference between human and canine CNGB3 cones in response to CNTF. (ClinicalTrials.gov number, NCT01648452.).",
keywords = "Achromatopsia, CNGB3, CNTF, CNTF-releasing implant, Cone photoreceptor, ECT implant, Human clinical trial, Rod photoreceptor",
author = "Zein, {Wadih M.} and Jeffrey, {Brett G.} and Wiley, {Henry E.} and Turriff, {Amy E.} and Tumminia, {Santa J.} and Weng Tao and Bush, {Ronald A.} and Dario Marangoni and Rong Wen and Wei, {Lisa L.} and Sieving, {Paul A.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1167/iovs.14-14860",
language = "English",
volume = "55",
pages = "6301--6308",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "10",

}

TY - JOUR

T1 - CNGB3-achromatopsia clinical trial with CNTF

T2 - Diminished rod pathway responses with no evidence of improvement in cone function

AU - Zein, Wadih M.

AU - Jeffrey, Brett G.

AU - Wiley, Henry E.

AU - Turriff, Amy E.

AU - Tumminia, Santa J.

AU - Tao, Weng

AU - Bush, Ronald A.

AU - Marangoni, Dario

AU - Wen, Rong

AU - Wei, Lisa L.

AU - Sieving, Paul A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - PURPOSE: Ciliary neurotrophic factor (CNTF) protects rod photoreceptors from retinal degenerative disease in multiple nonhuman models. Thus far, CNTF has failed to demonstrate rod protection in trials for human retinitis pigmentosa. Recently, CNTF was found to improve cone photoreceptor function in a canine CNGB3 achromatopsia model. This study explores whether this finding translates to humans with CNGB3 achromatopsia.METHODS: A five-subject, open-label Phase I/II study was initiated by implanting intraocular microcapsules releasing CNTF (nominally 20 ng/d) into one eye each of CNGB3 achromat participants. Fellow eyes served as untreated controls. Subjects were followed for 1 year.RESULTS: Pupil constriction in treated eyes gave evidence of intraocular CNTF release. Additionally, scotopic ERG responses were reduced, and dark-adapted psychophysical absolute thresholds were increased, attributable to diminished rod or rod pathway activity. Optical coherence tomography revealed that the cone-rich fovea underwent structural changes as the foveal hyporeflective zone (HRZ) became diminished in CNTF-treated eyes. No objectively measurable enhancement of cone function was found by assessments of visual acuity, mesopic increment sensitivity threshold, or the photopic ERG. Careful measurements of color hue discrimination showed no change. Nonetheless, subjects reported beneficial changes of visual function in the treated eyes, including reduced light sensitivity and aversion to bright light, which may trace to decreased effective ambient light from the pupillary constriction; further they noted slowed adaptation to darkness, consistent with CNTF action on rod photoreceptors.CONCLUSIONS: Ciliary neurotrophic factor did not measurably enhance cone function, which reveals a species difference between human and canine CNGB3 cones in response to CNTF. (ClinicalTrials.gov number, NCT01648452.).

AB - PURPOSE: Ciliary neurotrophic factor (CNTF) protects rod photoreceptors from retinal degenerative disease in multiple nonhuman models. Thus far, CNTF has failed to demonstrate rod protection in trials for human retinitis pigmentosa. Recently, CNTF was found to improve cone photoreceptor function in a canine CNGB3 achromatopsia model. This study explores whether this finding translates to humans with CNGB3 achromatopsia.METHODS: A five-subject, open-label Phase I/II study was initiated by implanting intraocular microcapsules releasing CNTF (nominally 20 ng/d) into one eye each of CNGB3 achromat participants. Fellow eyes served as untreated controls. Subjects were followed for 1 year.RESULTS: Pupil constriction in treated eyes gave evidence of intraocular CNTF release. Additionally, scotopic ERG responses were reduced, and dark-adapted psychophysical absolute thresholds were increased, attributable to diminished rod or rod pathway activity. Optical coherence tomography revealed that the cone-rich fovea underwent structural changes as the foveal hyporeflective zone (HRZ) became diminished in CNTF-treated eyes. No objectively measurable enhancement of cone function was found by assessments of visual acuity, mesopic increment sensitivity threshold, or the photopic ERG. Careful measurements of color hue discrimination showed no change. Nonetheless, subjects reported beneficial changes of visual function in the treated eyes, including reduced light sensitivity and aversion to bright light, which may trace to decreased effective ambient light from the pupillary constriction; further they noted slowed adaptation to darkness, consistent with CNTF action on rod photoreceptors.CONCLUSIONS: Ciliary neurotrophic factor did not measurably enhance cone function, which reveals a species difference between human and canine CNGB3 cones in response to CNTF. (ClinicalTrials.gov number, NCT01648452.).

KW - Achromatopsia

KW - CNGB3

KW - CNTF

KW - CNTF-releasing implant

KW - Cone photoreceptor

KW - ECT implant

KW - Human clinical trial

KW - Rod photoreceptor

UR - http://www.scopus.com/inward/record.url?scp=84908101924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908101924&partnerID=8YFLogxK

U2 - 10.1167/iovs.14-14860

DO - 10.1167/iovs.14-14860

M3 - Article

C2 - 25205868

AN - SCOPUS:84908101924

VL - 55

SP - 6301

EP - 6308

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 10

ER -